KINGSTON, Jamaica — The Ganja Growers and Producers Association of Jamaica (GGPAJ) has welcomed the recent reclassification of cannabis under United States (US) federal law from a Schedule I to a Schedule III substance, describing the development as a significant global shift with both opportunity and urgency for Jamaica’s ganja industry.

According to the GGPAJ, in a press release on Tuesday, the change, driven by recent US policy direction, is expected to ease research restrictions, improve access to financial services and further legitimise cannabis as a regulated medical commodity within the world’s largest economy.

However, GGPAJ cautions that while the move signals progress internationally, it also raises the stakes for Jamaica’s ability to compete and participate meaningfully in the evolving global market.

“This materially changes the operating environment for the global ganja industry — and Jamaican farmers need to read it as both an opening and a warning,” said Maurice Ellis, president of GGPAJ.

GGPAJ said the US reclassification is likely to accelerate medical research and clinical validation, product development and innovation and institutional investment and global partnerships.

It said for Jamaica, this could translate into increased demand for compliant, traceable and high-quality ganja products, particularly within the medicinal and export segments.

At the same time, the association emphasises that US operators will benefit from greater access to capital and banking, tax efficiencies, enhanced scalability and supply chain integration.

The association said this will likely result in faster industry consolidation and reduced production costs, creating a competitive environment that many Jamaican growers, particularly traditional and small-scale farmers, are not currently equipped to navigate.

“The recent rescheduling of cannabis in the United States presents a significant opportunity for jurisdictions that can move decisively and deploy capital at scale to capture emerging market share. However, it also heightens the competitive stakes globally,” said Andray McKenzie, vice president of GGPAJ.

“Despite Jamaica’s strong brand equity and deep cultural legacy in cannabis, there is a real risk that the country could be relegated to low-margin participation if it does not rapidly strengthen its regulatory efficiency, industrial capacity and commercial positioning,” McKenzie said.

“A critical enabler of this transition will be the role of financial institutions in unlocking accessible and appropriately structured financing, including dedicated funding windows to support research, manufacturing and industry scale-up. The window for action is narrow, and jurisdictions that respond with speed and coordination will secure disproportionate value in the evolving global market. Jamaica has the foundational assets to lead, but this will require urgent alignment of policy, capital and industry to fully realise its potential,” he added.

GGPAJ emphasised that Jamaica must act decisively to avoid being left behind.

“The global market is about to professionalise rapidly, and Jamaica is behind on regulatory efficiency and farmer inclusion,” Ellis added.

While welcoming the recent amended regulations, there remains a need for more simplified and accessible licensing frameworks. The association is calling for medicinal cannabis product innovation, development and approvals, meaningful integration of traditional and sacramental growers, alignment with international compliance and export standards, and strengthened support systems for small-scale farmers to transition and compete.

GGPAJ underscored that Jamaica’s global identity in ganja is rooted in its cultural, traditional and sacramental heritage — and that these stakeholders must remain central to the industry’s evolution. It said that without deliberate inclusion and policy reform, those who sustained the industry for generations risk being excluded from its economic future.

“The advantage will go to jurisdictions that can organise quickly,” Ellis stated.